Latest BioPharma News and In-Depth Analysis | BioPharma BoardRoom

01 January, 2026 | Thursday

Incyte's Pemazyre® (pemigatinib) Approved in Japan for Myeloid/Lymphoid Neoplasms (MLNs)

ncyte (Nasdaq:INCY) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fi...

March 28, 2023 | Tuesday | News

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas

Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from Astellas Acquiring leading global echinocandin, one of three...

January 24, 2023 | Tuesday | News

5
6
7
8
9
10
11
12
13
14

Partner Content

Cytiva Launches Fibro dT Platform to Accelerate High-Yield mRNA Purification
07 November, 2025
Avance Clinical Launches CNS Center of Excellence to Advance Global Biotech Trials
29 October, 2025
GSK and Empirico Enter Exclusive Licensing Agreement for Novel siRNA Candidate EMP-012 in COPD
29 October, 2025
Catalent Introduces New Corporate Brand to Champion “Missions That Matter” Across Global Healthcare
29 October, 2025
Lonza Accelerates the Future of Pharma QC with Acquisition of Redberry and Its Breakthrough Red One™ Rapid Microbiology Platform
29 October, 2025
BD Showcases Next-Generation Drug Delivery and RFID Traceability Solutions at CPhI 2025
28 October, 2025

BioPharma BreakThrough's

Editor Picks

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

Gene Editing Breakthroughs

Innovative Drug Discovery

Vaccine Development

Biologics and Therapeutic Antibodies

× Please select an option to participate in the poll.

View poll results More polls

× You have successfully cast your vote.

{{ optionDetail.option }} {{ optionDetail.percentage }}%

More polls

About Us Media Pack Contact Us Privacy Policy

© 2026 Biopharma Boardroom. All Rights Reserved.